Skip to main content

Table 2 Overall sequencing of biologic drug switches

From: The perplexity of prescribing and switching of biologic drugs in rheumatoid arthritis: a UK regional audit of practice

  Anti-TNFα Rituximab Tocilizumab Abatacept Total
n (%) n (%) n (%) n (%) n (%)
Anti-TNFα 84 (25.1) 172 (51.3) 21 (6.3) 10 (3.0) 287 (85.7)
n (%)
Rituximab 15 (4.4) - 26 (7.8) 4 (1.2) 45 (13.4)
n (%)
Tocilizumab 0 (0) 1 (0.3) - 2 (0.6) 3 (0.9)
n (%)
Abatacept 0 (0) 0 (0) 0 (0) - 0 (0)
n (%)
Total 99 (29.6) 173 (51.6) 47 (14.0) 16 (4.8) 335 (100)
n (%)